Share This

Topics Comments

  Next page > 
Cheung Kong VODone Limited Shenzhen International Holdings Limited Jiangxi Copper Company Limited REXLot Holdings Limited China Overseas Land & Investment Limited Chong Hing Bank Limited Agricultural Bank of China Limited Chow Tai Fook Jewellery Group Limited Capital VC Limited iShares A50 Standard Chartered Bank of Communications Bank of China China LotSynergy Holdings Limited agribank Agri Airlines Appl AUD Auto A Shares Brokers CAD fertilizer producers China Lottery Supermarket China Banks Communication Consumer China Econ Electricity China Finance China IT Petro Real Est China Resource Steel coal Commodity Beauty Drugs Enviro EURO Lang Simon Ting WongSir Andy Xie Expo Gambling Garment gas GBD Gold Gold Jew Gold mine Harbour Highways HK Apparel REITs Rentals HK Banks ETF HK Housing Market Real Est HK HK Stock iBond Infra Insure IPO jewel Mach Build Mat New Energy NZD Oil Paper Rare Earths Real Estate Market Food RMB Rising RMB RMB Bonds Shipbuilding Shipping Sports Stock Trend Taiwan Dollar (TWD) Textile Top 500 USD US Econ Util Water Yang Liu's 10 Stocks YEN Diary media Central Bank Monetary Policy Education Construction Emerging markets Nuclear power BillGross Cement HK retail logistics Swiss franc Social Security Fund Law Ka-Chung capital flow Financial and political policy Railway film Korean Won Roubini Faber Mobius
Topics Last reply time Nickname Content
Grand Pharmaceutical Group Limited 2024-12-03T12:27 財經茄呢啡 遠大醫藥公布公告稱,用於眼科術後抗炎鎮痛的全球創新激素納米混懸滴眼液GPN00833完成了國內III期臨床研究並成功達到了臨床終點。
Grand Pharmaceutical Group Limited 2024-12-03T12:27 財經茄呢啡 遠大醫藥公布自願性公告,宣布其全球創新放射性核素偶聯藥物TLX250-CDX在中國III期臨床研究已完成首例患者入組並給藥。該研究旨在評估TLX250-CDX在無創檢測腎透明細胞癌的安全性、耐受性及有效性,計劃入組82名患者。這一發展標志著公司在核藥抗腫瘤診療領域的主要研發發展。
Grand Pharmaceutical Group Limited 2024-12-03T12:27 財經茄呢啡 截至2024年11月28日收盤,遠大醫藥報收於4.55港元,上揚3.41%,換手率0.16%,成交量569.4萬股,成交額2566.69萬港元。投行對該股的評級以優於大市為主,近90天內共有1家投行給出優於大市評級。西部證券最新一份研報給予遠大醫藥買進評級。
Grand Pharmaceutical Group Limited 2024-11-26T12:53 財經茄呢啡 遠大醫藥在眼科領域已積累了十余年的發展經驗,公司是我國重要的眼科藥研發、生產及銷售綜合企業之一,並於業內率先提出打造集「預防+治療+保健」的「大五官生態圈」理念。產品管線方面,遠大醫藥眼科在售產品管線數量位居行業前列,公司不僅手握療效及商業化表現雙佳的拳頭產品(如國內治療干眼症的一線用藥瑞珠,以及國家中藥保護品種和血明目片等),還有一系列在研創新產品儲備,產品梯隊建設齊全完備。
Grand Pharmaceutical Group Limited 2024-11-19T12:45 財經茄呢啡 遠大醫藥公布公告,宣布與SIRTEX MEDICAL簽訂了2024分銷協議。依據協議,北京普爾偉業與成都普爾偉業將作為SIRTEX MEDICAL在中國的獨家經銷商,購買固定數量的產品進行轉售。2024分銷協議的有效期為自簽署之日起至2025年11月14日,期間北京普爾偉業將最多購買800套產品,而成都普爾偉業將最多購買200套產品。
Grand Pharmaceutical Group Limited 2024-11-05T12:44 財經茄呢啡 2024年10月18日,遠大醫藥集團有限公司(簡稱:遠大醫藥,股票代碼:00512.HK)心腦血管精准介入診療板塊國產首款可調節取栓支架鸕茲LUCI(國械注准:20243032073),正式取得國家藥品監督管理局的上市批准。
Grand Pharmaceutical Group Limited 2024-10-29T12:48 財經茄呢啡 心腦血管精准介入診療板塊是遠大醫藥核心戰略板塊之一。除本次獲批上市的鸕茲外,在神經介入方面,遠大醫藥自研自產的全球創新型神經介入產品OTW(OVER THE WIRE,同軸)顱內球囊擴張導管彩鷸、急性缺血性腦卒中治療產品封堵球囊導管鵜鶘以及用於建立神經血管及外周血管系統介入手術通路的遠端通路導管琵鷺和微導管蛇鵜均已於國內獲批上市。
Grand Pharmaceutical Group Limited 2024-10-29T12:48 財經茄呢啡 遠大醫藥今天公布公告稱,其用於治療急性缺血性卒中的可調節顱內取栓支架產品「鸕茲」日前已獲藥監局頒發醫療器械注冊證書。
Grand Pharmaceutical Group Limited 2024-10-08T12:43 財經茄呢啡 遠大醫藥近年來正加快布局核藥管線,財報顯示,在核藥抗腫瘤診療板塊,得益於創新產品放量,遠大醫藥該板塊收入約2.1億港元,同比提升約107.6%。
Grand Pharmaceutical Group Limited 2024-09-24T12:43 財經茄呢啡 此次收購對於遠大醫藥的呼吸及危重症板塊來說,具有多重意義。首先,它豐富了遠大醫藥的產品線,提升了它在該領域的市場競爭力。百濟制藥的鼻噴制劑產品與遠大醫藥現有的哮喘治療產品形成了良好的互補,共同做成了遠大醫藥集團在呼吸疾病領域的完整解決方案。
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.